DefiniGEN is a spin-out from the University of Cambridge, creating highly predictive disease cell models for preclinical research and drug development. The process of bringing new drugs to market is arduous, expensive and blighted by a high failure rate. DefiniGEN’s models help the biopharma industry to respond to these challenges, enabling highly relevant information on potential new drug efficacy to be realised in an accelerated manner.
Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth.Dr Marcus Yeo , CEO
Business funding insights
How to grow your company through acquisition
Gurinder Sunner, head of BGF in the Midlands considers ‘How to grow your company through acquisition’ In its simplest form,…
Infrastructure spending is only one part of the solution
The chancellor is right to back an investment-led recovery, but infrastructure is only part of the solution. Business funding is needed too.